ID
DB08970||
名称
Fluprednidene
描述
Fluprednidene is a corticosteroid.
cas号
2193-87-5
唯一标识码
FA517NS3N7
状态
solid
一般参考文献


experimental,
指示
药效学
作用机制
毒性
代谢
吸收
半衰期
分类
description:This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
direct-parent:21-hydroxysteroids
kingdom:Organic compounds
superclass:Lipids and lipid-like molecules
class:Steroids and steroid derivatives
subclass:Hydroxysteroids
alternative-parent:11-beta-hydroxysteroids
alternative-parent:17-hydroxysteroids
alternative-parent:20-oxosteroids
alternative-parent:3-oxo delta-1,4-steroids
alternative-parent:Alkyl fluorides
alternative-parent:Alpha-hydroxy ketones
alternative-parent:Cyclic alcohols and derivatives
alternative-parent:Cyclic ketones
alternative-parent:Delta-1,4-steroids
alternative-parent:Fluorohydrins
alternative-parent:Gluco/mineralocorticoids, progestogins and derivatives
alternative-parent:Halogenated steroids
alternative-parent:Hydrocarbon derivatives
alternative-parent:Organic oxides
alternative-parent:Organofluorides
alternative-parent:Primary alcohols
alternative-parent:Secondary alcohols
alternative-parent:Tertiary alcohols
substituent:11-beta-hydroxysteroid
substituent:11-hydroxysteroid
substituent:17-hydroxysteroid
substituent:20-oxosteroid
substituent:21-hydroxysteroid
substituent:3-oxo-delta-1,4-steroid
substituent:3-oxosteroid
substituent:9-halo-steroid
substituent:Alcohol
substituent:Aliphatic homopolycyclic compound
substituent:Alkyl fluoride
substituent:Alkyl halide
substituent:Alpha-hydroxy ketone
substituent:Carbonyl group
substituent:Cyclic alcohol
substituent:Cyclic ketone
substituent:Delta-1,4-steroid
substituent:Fluorohydrin
substituent:Halo-steroid
substituent:Halohydrin
substituent:Hydrocarbon derivative
substituent:Ketone
substituent:Organic oxide
substituent:Organic oxygen compound
substituent:Organofluoride
substituent:Organohalogen compound
substituent:Organooxygen compound
substituent:Oxosteroid
substituent:Pregnane-skeleton
substituent:Primary alcohol
substituent:Progestogin-skeleton
substituent:Secondary alcohol
substituent:Tertiary alcohol
消除途径
种类
Adrenal Cortex Hormones
D000305
Corticosteroids
D000305
Corticosteroids, Dermatological Preparations

Corticosteroids, Moderately Potent (Group II)

Cytochrome P-450 CYP3A Inducers
D065701
Cytochrome P-450 CYP3A Substrates

Cytochrome P-450 CYP3A4 Inducers
D065701
Cytochrome P-450 CYP3A4 Inducers (strength unknown)

Cytochrome P-450 CYP3A4 Substrates

Cytochrome P-450 CYP3A5 Inducers
D065701
Cytochrome P-450 CYP3A5 Inducers (strength unknown)

Cytochrome P-450 Enzyme Inducers
D065693
Cytochrome P-450 Substrates

Dermatologicals
D003879
Glucocorticoids
D005938
Hyperglycemia-Associated Agents

Immunosuppressive Agents
D007166
盐类
蛋白质结合
清除
同义词
国际品牌
配送量
产品
混合物
包装者
生产者
价格
受影响的生物体
剂量
form:Cream
route:
strength:500 mg/100g
atc代码
Corticosteroids, moderately potent, other combinations
CORTICOSTEROIDS, OTHER COMBINATIONS
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
DERMATOLOGICALS
Corticosteroids, moderately potent (group II)
CORTICOSTEROIDS, PLAIN
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
DERMATOLOGICALS
Corticosteroids, moderately potent, combinations with antibiotics
CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS
CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
DERMATOLOGICALS
fda标签
化学品安全技术说明书
专利
食物相互作用
药物相互作用
DB06643
The risk or severity of adverse effects can be increased when Denosumab is combined with Fluprednidene.
DB00008
The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fluprednidene.
DB00011
The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fluprednidene.
DB00018
The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Fluprednidene.
DB00022
The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Fluprednidene.
DB00033
The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Fluprednidene.
DB00034
The risk or severity of adverse effects can be increased when Interferon alfa-2a, Recombinant is combined with Fluprednidene.
DB00056
The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluprednidene.
DB00059
The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluprednidene.
DB00068
The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluprednidene.
DB00069
The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluprednidene.
DB00073
The risk or severity of adverse effects can be increased when Rituximab is combined with Fluprednidene.
DB00074
The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluprednidene.
DB00075
The risk or severity of adverse effects can be increased when Muromonab is combined with Fluprednidene.
DB00078
The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluprednidene.
DB00081
The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluprednidene.
DB00087
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluprednidene.
DB00092
The risk or severity of adverse effects can be increased when Alefacept is combined with Fluprednidene.
DB00095
The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluprednidene.
DB00098
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluprednidene.
DB00105
The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluprednidene.
DB00111
The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluprednidene.
DB00112
The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fluprednidene.
DB00120
The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluprednidene.
DB00242
The risk or severity of adverse effects can be increased when Cladribine is combined with Fluprednidene.
DB00262
The risk or severity of adverse effects can be increased when Carmustine is combined with Fluprednidene.
DB00276
The risk or severity of adverse effects can be increased when Amsacrine is combined with Fluprednidene.
DB00290
The risk or severity of adverse effects can be increased when Bleomycin is combined with Fluprednidene.
DB00291
The risk or severity of adverse effects can be increased when Chlorambucil is combined with Fluprednidene.
DB00293
The risk or severity of adverse effects can be increased when Raltitrexed is combined with Fluprednidene.
DB00305
The risk or severity of adverse effects can be increased when Mitomycin is combined with Fluprednidene.
DB00307
The risk or severity of adverse effects can be increased when Bexarotene is combined with Fluprednidene.
DB00322
The risk or severity of adverse effects can be increased when Floxuridine is combined with Fluprednidene.
DB00352
The risk or severity of adverse effects can be increased when Tioguanine is combined with Fluprednidene.
DB00380
The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluprednidene.
DB00428
The risk or severity of adverse effects can be increased when Streptozocin is combined with Fluprednidene.
DB00432
The risk or severity of adverse effects can be increased when Trifluridine is combined with Fluprednidene.
DB00441
The risk or severity of adverse effects can be increased when Gemcitabine is combined with Fluprednidene.
DB00445
The risk or severity of adverse effects can be increased when Epirubicin is combined with Fluprednidene.
DB00446
The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Fluprednidene.
DB00480
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Fluprednidene.
DB00488
The risk or severity of adverse effects can be increased when Altretamine is combined with Fluprednidene.
DB00495
The risk or severity of adverse effects can be increased when Zidovudine is combined with Fluprednidene.
DB00526
The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Fluprednidene.
DB00544
The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fluprednidene.
DB00550
The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Fluprednidene.
DB00552
The risk or severity of adverse effects can be increased when Pentostatin is combined with Fluprednidene.
DB00601
The risk or severity of adverse effects can be increased when Linezolid is combined with Fluprednidene.
DB00631
The risk or severity of adverse effects can be increased when Clofarabine is combined with Fluprednidene.
DB00642
The risk or severity of adverse effects can be increased when Pemetrexed is combined with Fluprednidene.
DB00688
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fluprednidene.
DB00755
The risk or severity of adverse effects can be increased when Tretinoin is combined with Fluprednidene.
DB00763
The risk or severity of adverse effects can be increased when Methimazole is combined with Fluprednidene.
DB00851
The risk or severity of adverse effects can be increased when Dacarbazine is combined with Fluprednidene.
DB00853
The risk or severity of adverse effects can be increased when Temozolomide is combined with Fluprednidene.
DB00859
The risk or severity of adverse effects can be increased when Penicillamine is combined with Fluprednidene.
DB00928
The risk or severity of adverse effects can be increased when Azacitidine is combined with Fluprednidene.
DB00958
The risk or severity of adverse effects can be increased when Carboplatin is combined with Fluprednidene.
DB00970
The risk or severity of adverse effects can be increased when Dactinomycin is combined with Fluprednidene.
DB00993
The risk or severity of adverse effects can be increased when Azathioprine is combined with Fluprednidene.
DB01005
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Fluprednidene.
DB01024
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluprednidene.
DB01030
The risk or severity of adverse effects can be increased when Topotecan is combined with Fluprednidene.
DB01033
The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Fluprednidene.
DB01041
The risk or severity of adverse effects can be increased when Thalidomide is combined with Fluprednidene.
DB01042
The risk or severity of adverse effects can be increased when Melphalan is combined with Fluprednidene.
DB01073
The risk or severity of adverse effects can be increased when Fludarabine is combined with Fluprednidene.
DB01099
The risk or severity of adverse effects can be increased when Flucytosine is combined with Fluprednidene.
DB01101
The risk or severity of adverse effects can be increased when Capecitabine is combined with Fluprednidene.
DB01168
The risk or severity of adverse effects can be increased when Procarbazine is combined with Fluprednidene.
DB01169
The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fluprednidene.
DB01177
The risk or severity of adverse effects can be increased when Idarubicin is combined with Fluprednidene.
DB01196
The risk or severity of adverse effects can be increased when Estramustine is combined with Fluprednidene.
DB01204
The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Fluprednidene.
DB01206
The risk or severity of adverse effects can be increased when Lomustine is combined with Fluprednidene.
DB01257
The risk or severity of adverse effects can be increased when Eculizumab is combined with Fluprednidene.
DB01262
The risk or severity of adverse effects can be increased when Decitabine is combined with Fluprednidene.
DB01280
The risk or severity of adverse effects can be increased when Nelarabine is combined with Fluprednidene.
DB01423
The risk or severity of adverse effects can be increased when Stepronin is combined with Fluprednidene.
DB01611
The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Fluprednidene.
DB01816
The risk or severity of adverse effects can be increased when Castanospermine is combined with Fluprednidene.
DB02546
The risk or severity of adverse effects can be increased when Vorinostat is combined with Fluprednidene.
DB02806
The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Fluprednidene.
DB03523
The risk or severity of adverse effects can be increased when Brequinar is combined with Fluprednidene.
DB04951
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Fluprednidene.
DB05258
The risk or severity of adverse effects can be increased when Interferon alfa is combined with Fluprednidene.
DB05259
The risk or severity of adverse effects can be increased when Glatiramer is combined with Fluprednidene.
DB05260
The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Fluprednidene.
DB05459
The risk or severity of adverse effects can be increased when Briakinumab is combined with Fluprednidene.
DB05472
The risk or severity of adverse effects can be increased when Human interferon omega-1 is combined with Fluprednidene.
DB06612
The risk or severity of adverse effects can be increased when Mepolizumab is combined with Fluprednidene.
DB06662
The risk or severity of adverse effects can be increased when Abetimus is combined with Fluprednidene.
DB06681
The risk or severity of adverse effects can be increased when Belatacept is combined with Fluprednidene.
DB06769
The risk or severity of adverse effects can be increased when Bendamustine is combined with Fluprednidene.
DB06813
The risk or severity of adverse effects can be increased when Pralatrexate is combined with Fluprednidene.
DB08059
The risk or severity of adverse effects can be increased when Wortmannin is combined with Fluprednidene.
DB08871
The risk or severity of adverse effects can be increased when Eribulin is combined with Fluprednidene.
DB08879
The risk or severity of adverse effects can be increased when Belimumab is combined with Fluprednidene.
DB08880
The risk or severity of adverse effects can be increased when Teriflunomide is combined with Fluprednidene.
DB08889
The risk or severity of adverse effects can be increased when Carfilzomib is combined with Fluprednidene.
DB08908
The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Fluprednidene.
DB08935
The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Fluprednidene.
DB09033
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Vedolizumab.
DB09052
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Blinatumomab.
DB09077
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Dinutuximab.
DB09082
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Vilanterol.
DB09122
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Peginterferon beta-1a.
DB09312
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Antilymphocyte immunoglobulin (horse).
DB11569
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Ixekizumab.
DB11580
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Ravulizumab.
DB11616
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Pirarubicin.
DB11693
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Voclosporin.
DB11708
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Peficitinib.
DB11767
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Sarilumab.
DB11776
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Brodalumab.
DB11803
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Sirukumab.
DB11834
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Guselkumab.
DB12612
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Ozanimod.
DB12617
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Mizoribine.
DB12692
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Gusperimus.
DB12814
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Cepeginterferon alfa-2B.
DB12902
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Trofosfamide.
DB12947
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Doxifluridine.
DB12991
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Deoxyspergualin.
DB12996
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Acteoside.
DB13014
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Hypericin.
DB13068
The risk or severity of adverse effects can be increased when Fluprednidene is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
DB13241
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Begelomab.
DB14066
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Tetrandrine.
DB14219
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Monomethyl fumarate.
DB14762
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Risankizumab.
DB14919
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Rozanolixizumab.
DB15253
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Bleselumab.
DB00005
The risk or severity of adverse effects can be increased when Etanercept is combined with Fluprednidene.
DB00026
The risk or severity of adverse effects can be increased when Anakinra is combined with Fluprednidene.
DB00051
The risk or severity of adverse effects can be increased when Adalimumab is combined with Fluprednidene.
DB00065
The risk or severity of adverse effects can be increased when Infliximab is combined with Fluprednidene.
DB01281
The risk or severity of adverse effects can be increased when Abatacept is combined with Fluprednidene.
DB04956
The risk or severity of adverse effects can be increased when Afelimomab is combined with Fluprednidene.
DB05676
The risk or severity of adverse effects can be increased when Apremilast is combined with Fluprednidene.
DB06168
The risk or severity of adverse effects can be increased when Canakinumab is combined with Fluprednidene.
DB06273
The risk or severity of adverse effects can be increased when Tocilizumab is combined with Fluprednidene.
DB06372
The risk or severity of adverse effects can be increased when Rilonacept is combined with Fluprednidene.
DB06674
The risk or severity of adverse effects can be increased when Golimumab is combined with Fluprednidene.
DB08904
The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Fluprednidene.
DB09029
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Secukinumab.
DB09036
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Siltuximab.
DB14724
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Emapalumab.
DB01394
The risk or severity of adverse effects can be increased when Colchicine is combined with Fluprednidene.
DB00180
The risk or severity of adverse effects can be increased when Flunisolide is combined with Fluprednidene.
DB00394
The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Fluprednidene.
DB00443
The risk or severity of adverse effects can be increased when Betamethasone is combined with Fluprednidene.
DB00588
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Fluprednidene.
DB00591
The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Fluprednidene.
DB00620
The risk or severity of adverse effects can be increased when Triamcinolone is combined with Fluprednidene.
DB00635
The risk or severity of adverse effects can be increased when Prednisone is combined with Fluprednidene.
DB00687
The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Fluprednidene.
DB00860
The risk or severity of adverse effects can be increased when Prednisolone is combined with Fluprednidene.
DB00959
The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Fluprednidene.
DB01222
The risk or severity of adverse effects can be increased when Budesonide is combined with Fluprednidene.
DB01234
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Fluprednidene.
DB01285
The risk or severity of adverse effects can be increased when Corticotropin is combined with Fluprednidene.
DB01380
The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Fluprednidene.
DB01384
The risk or severity of adverse effects can be increased when Paramethasone is combined with Fluprednidene.
DB01410
The risk or severity of adverse effects can be increased when Ciclesonide is combined with Fluprednidene.
DB04630
The risk or severity of adverse effects can be increased when Aldosterone is combined with Fluprednidene.
DB08906
The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Fluprednidene.
DB09091
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Tixocortol.
DB09378
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Fluprednisolone.
DB09383
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Meprednisone.
DB11487
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Dexamethasone isonicotinate.
DB11529
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Melengestrol.
DB11921
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Deflazacort.
DB13003
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Cortivazol.
DB13208
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Prednylidene.
DB13223
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Fluocortin.
DB13491
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Fluperolone.
DB13843
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Cloprednol.
DB13856
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Fluclorolone.
DB13867
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Fluticasone.
DB14512
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Mometasone furoate.
DB14539
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Hydrocortisone acetate.
DB14545
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Hydrocortisone succinate.
DB00694
The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fluprednidene.
DB00987
The risk or severity of adverse effects can be increased when Cytarabine is combined with Fluprednidene.
DB05015
The risk or severity of adverse effects can be increased when Belinostat is combined with Fluprednidene.
DB01013
The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Fluprednidene.
DB01047
The risk or severity of adverse effects can be increased when Fluocinonide is combined with Fluprednidene.
DB14540
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Hydrocortisone butyrate.
DB00547
The risk or severity of adverse effects can be increased when Desoximetasone is combined with Fluprednidene.
DB00764
The risk or severity of adverse effects can be increased when Mometasone is combined with Fluprednidene.
DB08971
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Fluocortolone.
DB11750
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Clobetasol.
DB00619
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Imatinib.
DB09053
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Ibrutinib.
DB00324
The risk or severity of adverse effects can be increased when Fluorometholone is combined with Fluprednidene.
DB09095
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Difluocortolone.
DB00108
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Natalizumab.
DB00337
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Fluprednidene.
DB01656
Roflumilast may increase the immunosuppressive activities of Fluprednidene.
DB06688
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Fluprednidene.
DB09063
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Ceritinib.
DB00041
The therapeutic efficacy of Aldesleukin can be decreased when used in combination with Fluprednidene.
DB09067
The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Fluprednidene.
DB01609
The risk or severity of gastrointestinal ulceration and gastrointestinal irritation can be increased when Fluprednidene is combined with Deferasirox.
DB00070
The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Fluprednidene.
DB06205
The therapeutic efficacy of Hyaluronidase (human recombinant) can be decreased when used in combination with Fluprednidene.
DB14740
The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluprednidene.
DB00681
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Amphotericin B.
DB00221
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Isoetharine.
DB00368
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Norepinephrine.
DB00397
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Phenylpropanolamine.
DB00668
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Epinephrine.
DB00816
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Orciprenaline.
DB00841
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Dobutamine.
DB00867
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Ritodrine.
DB00901
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Bitolterol.
DB00938
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Salmeterol.
DB00983
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Formoterol.
DB01001
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Salbutamol.
DB01064
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Isoprenaline.
DB01102
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Arbutamine.
DB01274
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Arformoterol.
DB01288
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Fenoterol.
DB01291
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Pirbuterol.
DB01363
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Ephedra sinica root.
DB01366
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Procaterol.
DB01407
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Clenbuterol.
DB04846
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Celiprolol.
DB05039
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Indacaterol.
DB06262
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Droxidopa.
DB06814
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Protokylol.
DB08957
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Hexoprenaline.
DB09080
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Olodaterol.
DB09273
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Doxofylline.
DB11124
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Racepinephrine.
DB11587
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Etafedrine.
DB11871
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with PF-00610355.
DB12100
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Abediterol.
DB12526
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Batefenterol.
DB13139
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Levosalbutamol.
DB00834
The therapeutic efficacy of Fluprednidene can be decreased when used in combination with Mifepristone.
DB00648
The serum concentration of Fluprednidene can be decreased when it is combined with Mitotane.
DB00266
Fluprednidene may increase the anticoagulant activities of Dicoumarol.
DB00498
Fluprednidene may increase the anticoagulant activities of Phenindione.
DB00682
Fluprednidene may increase the anticoagulant activities of Warfarin.
DB00946
Fluprednidene may increase the anticoagulant activities of Phenprocoumon.
DB01418
Fluprednidene may increase the anticoagulant activities of Acenocoumarol.
DB03410
Fluprednidene may increase the anticoagulant activities of 4-hydroxycoumarin.
DB04665
Fluprednidene may increase the anticoagulant activities of Coumarin.
DB08496
Fluprednidene may increase the anticoagulant activities of (R)-warfarin.
DB08794
Fluprednidene may increase the anticoagulant activities of Ethyl biscoumacetate.
DB13136
Fluprednidene may increase the anticoagulant activities of Fluindione.
DB13275
Fluprednidene may increase the anticoagulant activities of Clorindione.
DB13347
Fluprednidene may increase the anticoagulant activities of Diphenadione.
DB13451
Fluprednidene may increase the anticoagulant activities of Tioclomarol.
DB14055
Fluprednidene may increase the anticoagulant activities of (S)-Warfarin.
DB01015
The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Fluprednidene.
DB01097
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Leflunomide.
DB08895
Fluprednidene may increase the immunosuppressive activities of Tofacitinib.
DB00072
Trastuzumab may increase the neutropenic activities of Fluprednidene.
DB08868
Fluprednidene may increase the immunosuppressive activities of Fingolimod.
DB09220
The risk or severity of ulceration can be increased when Fluprednidene is combined with Nicorandil.
DB00864
Tacrolimus may increase the immunosuppressive activities of Fluprednidene.
DB00146
The therapeutic efficacy of Calcifediol can be decreased when used in combination with Fluprednidene.
DB00153
The therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Fluprednidene.
DB01070
The therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Fluprednidene.
DB01436
The therapeutic efficacy of Alfacalcidol can be decreased when used in combination with Fluprednidene.
DB04258
The therapeutic efficacy of Seocalcitol can be decreased when used in combination with Fluprednidene.
DB04796
The therapeutic efficacy of Inecalcitol can be decreased when used in combination with Fluprednidene.
DB04891
The therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Fluprednidene.
DB05295
The therapeutic efficacy of Eldecalcitol can be decreased when used in combination with Fluprednidene.
DB06117
The therapeutic efficacy of 1alpha,24S-Dihydroxyvitamin D2 can be decreased when used in combination with Fluprednidene.
DB06194
The therapeutic efficacy of Elocalcitol can be decreased when used in combination with Fluprednidene.
DB06272
The therapeutic efficacy of Maxacalcitol can be decreased when used in combination with Fluprednidene.
DB06410
The therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Fluprednidene.
DB13097
The therapeutic efficacy of 1alpha-Hydroxyvitamin D5 can be decreased when used in combination with Fluprednidene.
DB11094
The therapeutic efficacy of Vitamin D can be decreased when used in combination with Fluprednidene.
DB00136
The therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluprednidene.
DB00169
The therapeutic efficacy of Cholecalciferol can be decreased when used in combination with Fluprednidene.
DB00910
The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Fluprednidene.
DB12025
The serum concentration of Triptolide can be increased when it is combined with Fluprednidene.
DB00294
The serum concentration of Etonogestrel can be increased when it is combined with Fluprednidene.
DB00304
The serum concentration of Desogestrel can be increased when it is combined with Fluprednidene.
DB00351
The serum concentration of Megestrol acetate can be increased when it is combined with Fluprednidene.
DB00367
The serum concentration of Levonorgestrel can be increased when it is combined with Fluprednidene.
DB00717
The serum concentration of Norethisterone can be increased when it is combined with Fluprednidene.
DB00823
The serum concentration of Ethynodiol diacetate can be increased when it is combined with Fluprednidene.
DB00977
The serum concentration of Ethinylestradiol can be increased when it is combined with Fluprednidene.
DB01357
The serum concentration of Mestranol can be increased when it is combined with Fluprednidene.
DB04066
The serum concentration of p-Coumaric acid can be increased when it is combined with Fluprednidene.
DB04574
The serum concentration of Estrone sulfate can be increased when it is combined with Fluprednidene.
DB04682
The serum concentration of Octylphenoxy polyethoxyethanol can be increased when it is combined with Fluprednidene.
DB04839
The serum concentration of Cyproterone acetate can be increased when it is combined with Fluprednidene.
DB06266
The serum concentration of Lonidamine can be increased when it is combined with Fluprednidene.
DB06713
The serum concentration of Norelgestromin can be increased when it is combined with Fluprednidene.
DB06730
The serum concentration of Gestodene can be increased when it is combined with Fluprednidene.
DB06789
The serum concentration of Hydroxyprogesterone caproate can be increased when it is combined with Fluprednidene.
DB09371
The serum concentration of Norethynodrel can be increased when it is combined with Fluprednidene.
DB09389
The serum concentration of Norgestrel can be increased when it is combined with Fluprednidene.
DB09401
The serum concentration of Isosorbide can be increased when it is combined with Fluprednidene.
DB11507
The serum concentration of Cloprostenol can be increased when it is combined with Fluprednidene.
DB11619
The serum concentration of Gestrinone can be increased when it is combined with Fluprednidene.
DB11636
The serum concentration of Nomegestrol can be increased when it is combined with Fluprednidene.
DB12474
The serum concentration of Lynestrenol can be increased when it is combined with Fluprednidene.
DB13044
The serum concentration of Gossypol can be increased when it is combined with Fluprednidene.
DB13310
The serum concentration of Ormeloxifene can be increased when it is combined with Fluprednidene.
DB13528
The serum concentration of Chlormadinone can be increased when it is combined with Fluprednidene.
DB13563
The serum concentration of Norgestrienone can be increased when it is combined with Fluprednidene.
DB13685
The serum concentration of Quingestanol can be increased when it is combined with Fluprednidene.
DB13857
The serum concentration of Demegestone can be increased when it is combined with Fluprednidene.
DB13866
The serum concentration of Etynodiol can be increased when it is combined with Fluprednidene.
DB13981
The serum concentration of Nomegestrol acetate can be increased when it is combined with Fluprednidene.
DB14678
The serum concentration of Norethindrone enanthate can be increased when it is combined with Fluprednidene.
DB01395
The serum concentration of Fluprednidene can be increased when it is combined with Drospirenone.
DB00396
The serum concentration of Progesterone can be increased when it is combined with Fluprednidene.
DB00783
The serum concentration of Estradiol can be increased when it is combined with Fluprednidene.
DB13953
The serum concentration of Estradiol benzoate can be increased when it is combined with Fluprednidene.
DB13954
The serum concentration of Estradiol cypionate can be increased when it is combined with Fluprednidene.
DB13956
The serum concentration of Estradiol valerate can be increased when it is combined with Fluprednidene.
DB00255
The serum concentration of Fluprednidene can be increased when it is combined with Diethylstilbestrol.
DB00603
The serum concentration of Fluprednidene can be increased when it is combined with Medroxyprogesterone acetate.
DB00957
The serum concentration of Fluprednidene can be increased when it is combined with Norgestimate.
DB08867
The serum concentration of Fluprednidene can be increased when it is combined with Ulipristal.
DB00218
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Moxifloxacin.
DB00467
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Enoxacin.
DB00487
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Pefloxacin.
DB00685
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Trovafloxacin.
DB00779
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Nalidixic acid.
DB00817
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Rosoxacin.
DB00827
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Cinoxacin.
DB00978
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Lomefloxacin.
DB01044
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Gatifloxacin.
DB01155
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Gemifloxacin.
DB01165
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Ofloxacin.
DB01208
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Sparfloxacin.
DB01405
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Temafloxacin.
DB04576
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Fleroxacin.
DB05488
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Technetium Tc-99m ciprofloxacin.
DB06160
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Garenoxacin.
DB06600
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Nemonoxacin.
DB08972
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Flumequine.
DB11404
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Enrofloxacin.
DB11443
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Orbifloxacin.
DB11491
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Sarafloxacin.
DB11511
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Difloxacin.
DB11774
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Pazufloxacin.
DB11892
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Prulifloxacin.
DB13261
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Sitafloxacin.
DB13627
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Oxolinic acid.
DB13772
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Rufloxacin.
DB13823
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Pipemidic acid.
DB00365
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Grepafloxacin.
DB00537
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Ciprofloxacin.
DB01059
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Norfloxacin.
DB01137
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Levofloxacin.
DB11943
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Delafloxacin.
DB00310
Fluprednidene may increase the hypokalemic activities of Chlorthalidone.
DB00524
Fluprednidene may increase the hypokalemic activities of Metolazone.
DB00808
Fluprednidene may increase the hypokalemic activities of Indapamide.
DB01325
Fluprednidene may increase the hypokalemic activities of Quinethazone.
DB13989
Fluprednidene may increase the hypokalemic activities of Epitizide.
DB00621
The risk or severity of fluid retention can be increased when Fluprednidene is combined with Oxandrolone.
DB01185
The risk or severity of fluid retention can be increased when Fluprednidene is combined with Fluoxymesterone.
DB06718
The risk or severity of fluid retention can be increased when Fluprednidene is combined with Stanozolol.
DB12461
The risk or severity of fluid retention can be increased when Fluprednidene is combined with GLPG-0492.
DB01406
The risk or severity of fluid retention can be increased when Fluprednidene is combined with Danazol.
DB06412
The risk or severity of fluid retention can be increased when Fluprednidene is combined with Oxymetholone.
DB01377
The bioavailability of Fluprednidene can be decreased when combined with Magnesium oxide.
DB01390
The bioavailability of Fluprednidene can be decreased when combined with Sodium bicarbonate.
DB06723
The bioavailability of Fluprednidene can be decreased when combined with Aluminum hydroxide.
DB06724
The bioavailability of Fluprednidene can be decreased when combined with Calcium carbonate.
DB08938
The bioavailability of Fluprednidene can be decreased when combined with Magaldrate.
DB09104
The bioavailability of Fluprednidene can be decreased when combined with Magnesium hydroxide.
DB09281
The bioavailability of Fluprednidene can be decreased when combined with Magnesium trisilicate.
DB09481
The bioavailability of Fluprednidene can be decreased when combined with Magnesium carbonate.
DB13249
The bioavailability of Fluprednidene can be decreased when combined with Magnesium silicate.
DB13280
The bioavailability of Fluprednidene can be decreased when combined with Aluminium acetoacetate.
DB13322
The bioavailability of Fluprednidene can be decreased when combined with Hydrotalcite.
DB13486
The bioavailability of Fluprednidene can be decreased when combined with Magnesium peroxide.
DB13595
The bioavailability of Fluprednidene can be decreased when combined with Almasilate.
DB13626
The bioavailability of Fluprednidene can be decreased when combined with Aluminium glycinate.
DB13650
The bioavailability of Fluprednidene can be decreased when combined with Aloglutamol.
DB13829
The bioavailability of Fluprednidene can be decreased when combined with Calcium silicate.
DB14517
The bioavailability of Fluprednidene can be decreased when combined with Aluminium phosphate.
DB00214
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Torasemide.
DB00695
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Furosemide.
DB00887
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Bumetanide.
DB00903
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Etacrynic acid.
DB02925
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Piretanide.
DB08961
The risk or severity of hypokalemia can be increased when Fluprednidene is combined with Azosemide.
DB00328
The risk or severity of gastrointestinal irritation can be increased when Indomethacin is combined with Fluprednidene.
DB00795
The risk or severity of gastrointestinal irritation can be increased when Sulfasalazine is combined with Fluprednidene.
DB11466
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Tepoxalin.
DB00159
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Icosapent.
DB00461
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Nabumetone.
DB00465
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Ketorolac.
DB00469
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Tenoxicam.
DB00500
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Tolmetin.
DB00554
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Piroxicam.
DB00573
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Fenoprofen.
DB00605
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Sulindac.
DB00712
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Flurbiprofen.
DB00749
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Etodolac.
DB00784
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Mefenamic acid.
DB00788
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Naproxen.
DB00821
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Carprofen.
DB00939
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Meclofenamic acid.
DB00991
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Oxaprozin.
DB01009
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Ketoprofen.
DB01283
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Lumiracoxib.
DB01397
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Magnesium salicylate.
DB01399
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Salsalate.
DB01401
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Choline magnesium trisalicylate.
DB01419
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Antrafenine.
DB01600
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Tiaprofenic acid.
DB02224
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Taxifolin.
DB03585
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Oxyphenbutazone.
DB04725
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Licofelone.
DB04812
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Benoxaprofen.
DB05095
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Cimicoxib.
DB06725
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Lornoxicam.
DB06736
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Aceclofenac.
DB06737
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Zaltoprofen.
DB07402
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Azapropazone.
DB08797
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Salicylamide.
DB08940
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Kebuzone.
DB08942
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Isoxicam.
DB08951
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Indoprofen.
DB08955
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Ibuproxam.
DB08976
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Floctafenine.
DB08981
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Fenbufen.
DB08984
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Etofenamate.
DB08991
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Epirizole.
DB09084
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Benzydamine.
DB09213
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Dexibuprofen.
DB09214
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Dexketoprofen.
DB09215
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Droxicam.
DB09217
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Firocoxib.
DB09218
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Clonixin.
DB09285
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Morniflumate.
DB09295
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Talniflumate.
DB11455
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Robenacoxib.
DB11518
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Flunixin.
DB12399
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Polmacoxib.
DB12545
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Indobufen.
DB12610
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Ebselen.
DB13001
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Tinoridine.
DB13167
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Alclofenac.
DB13217
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Fentiazac.
DB13232
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Suxibuzone.
DB13286
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Bumadizone.
DB13314
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Alminoprofen.
DB13371
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Difenpiramide.
DB13407
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Nifenazone.
DB13432
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Lonazolac.
DB13481
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Tenidap.
DB13524
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Propyphenazone.
DB13527
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Proglumetacin.
DB13544
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Ethenzamide.
DB13629
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Mofebutazone.
DB13649
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Proquazone.
DB13657
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Benorilate.
DB13722
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Pirprofen.
DB13783
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Acemetacin.
DB13860
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Imidazole salicylate.
DB14059
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with SC-236.
DB14060
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with NS-398.
DB14938
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Flurbiprofen axetil.
DB00244
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Mesalazine.
DB00861
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Diflunisal.
DB00936
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Salicylic acid.
DB01014
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Balsalazide.
DB01250
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Olsalazine.
DB12445
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Nitroaspirin.
DB13538
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Guacetisal.
DB13612
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Carbaspirin calcium.
DB00482
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Celecoxib.
DB00533
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Rofecoxib.
DB00580
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Valdecoxib.
DB00586
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Diclofenac.
DB00812
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Phenylbutazone.
DB00814
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Meloxicam.
DB01050
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Ibuprofen.
DB01424
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Aminophenazone.
DB01435
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Antipyrine.
DB01628
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Etoricoxib.
DB04743
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Nimesulide.
DB04817
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Metamizole.
DB04828
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Zomepirac.
DB08439
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Parecoxib.
DB09216
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Tolfenamic acid.
DB09288
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Propacetamol.
DB09212
The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Loxoprofen.
DB00515
The therapeutic efficacy of Fluprednidene can be decreased when used in combination with Cisplatin.
DB00888
The therapeutic efficacy of Fluprednidene can be decreased when used in combination with Mechlorethamine.
DB04572
The therapeutic efficacy of Fluprednidene can be decreased when used in combination with Thiotepa.
DB00871
The therapeutic efficacy of Terbutaline can be decreased when used in combination with Fluprednidene.
DB01408
The therapeutic efficacy of Bambuterol can be decreased when used in combination with Fluprednidene.
DB00382
The therapeutic efficacy of Tacrine can be decreased when used in combination with Fluprednidene.
DB00391
The therapeutic efficacy of Sulpiride can be decreased when used in combination with Fluprednidene.
DB00392
The therapeutic efficacy of Profenamine can be decreased when used in combination with Fluprednidene.
DB00508
The therapeutic efficacy of Triflupromazine can be decreased when used in combination with Fluprednidene.
DB00527
The therapeutic efficacy of Cinchocaine can be decreased when used in combination with Fluprednidene.
DB00585
The therapeutic efficacy of Nizatidine can be decreased when used in combination with Fluprednidene.
DB00677
The therapeutic efficacy of Isoflurophate can be decreased when used in combination with Fluprednidene.
DB00711
The therapeutic efficacy of Diethylcarbamazine can be decreased when used in combination with Fluprednidene.
DB00721
The therapeutic efficacy of Procaine can be decreased when used in combination with Fluprednidene.
DB00805
The therapeutic efficacy of Minaprine can be decreased when used in combination with Fluprednidene.
DB00941
The therapeutic efficacy of Hexafluronium can be decreased when used in combination with Fluprednidene.
DB00944
The therapeutic efficacy of Demecarium can be decreased when used in combination with Fluprednidene.
DB00981
The therapeutic efficacy of Physostigmine can be decreased when used in combination with Fluprednidene.
DB01010
The therapeutic efficacy of Edrophonium can be decreased when used in combination with Fluprednidene.
DB01035
The therapeutic efficacy of Procainamide can be decreased when used in combination with Fluprednidene.
DB01043
The therapeutic efficacy of Memantine can be decreased when used in combination with Fluprednidene.
DB01122
The therapeutic efficacy of Ambenonium can be decreased when used in combination with Fluprednidene.
DB01381
The therapeutic efficacy of Ginkgo biloba can be decreased when used in combination with Fluprednidene.
DB01400
The therapeutic efficacy of Neostigmine can be decreased when used in combination with Fluprednidene.
DB02365
The therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Fluprednidene.
DB04864
The therapeutic efficacy of Huperzine A can be decreased when used in combination with Fluprednidene.
DB04892
The therapeutic efficacy of Phenserine can be decreased when used in combination with Fluprednidene.
DB05386
The therapeutic efficacy of Regramostim can be decreased when used in combination with Fluprednidene.
DB06692
The therapeutic efficacy of Aprotinin can be decreased when used in combination with Fluprednidene.
DB06756
The therapeutic efficacy of Glycine betaine can be decreased when used in combination with Fluprednidene.
DB11390
The therapeutic efficacy of Coumaphos can be decreased when used in combination with Fluprednidene.
DB11397
The therapeutic efficacy of Dichlorvos can be decreased when used in combination with Fluprednidene.
DB11412
The therapeutic efficacy of Fenthion can be decreased when used in combination with Fluprednidene.
DB11473
The therapeutic efficacy of Metrifonate can be decreased when used in combination with Fluprednidene.
DB12482
The therapeutic efficacy of Acotiamide can be decreased when used in combination with Fluprednidene.
DB13058
The therapeutic efficacy of Methanesulfonyl Fluoride can be decreased when used in combination with Fluprednidene.
DB13495
The therapeutic efficacy of Paraoxon can be decreased when used in combination with Fluprednidene.
DB13503
The therapeutic efficacy of Tyrothricin can be decreased when used in combination with Fluprednidene.
DB13668
The therapeutic efficacy of Ipidacrine can be decreased when used in combination with Fluprednidene.
DB13694
The therapeutic efficacy of Distigmine can be decreased when used in combination with Fluprednidene.
DB14031
The therapeutic efficacy of Tretamine can be decreased when used in combination with Fluprednidene.
DB15317
The therapeutic efficacy of Posiphen can be decreased when used in combination with Fluprednidene.
DB00483
The therapeutic efficacy of Fluprednidene can be decreased when used in combination with Gallamine triethiodide.
DB01199
The therapeutic efficacy of Fluprednidene can be decreased when used in combination with Tubocurarine.
DB01245
The therapeutic efficacy of Fluprednidene can be decreased when used in combination with Decamethonium.
DB01337
The therapeutic efficacy of Fluprednidene can be decreased when used in combination with Pancuronium.
DB01338
The therapeutic efficacy of Fluprednidene can be decreased when used in combination with Pipecuronium.
DB00477
The therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Fluprednidene.
DB00545
The therapeutic efficacy of Pyridostigmine can be decreased when used in combination with Fluprednidene.
DB00989
The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Fluprednidene.
DB02845
The therapeutic efficacy of Methylphosphinic Acid can be decreased when used in combination with Fluprednidene.
DB00082
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Fluprednidene.
DB00358
The therapeutic efficacy of Mefloquine can be decreased when used in combination with Fluprednidene.
DB00674
The therapeutic efficacy of Galantamine can be decreased when used in combination with Fluprednidene.
DB00843
The therapeutic efficacy of Donepezil can be decreased when used in combination with Fluprednidene.
DB01221
The therapeutic efficacy of Ketamine can be decreased when used in combination with Fluprednidene.
DB01233
The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Fluprednidene.
DB06774
The therapeutic efficacy of Capsaicin can be decreased when used in combination with Fluprednidene.
DB00202
The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Fluprednidene.
DB00416
The risk or severity of myopathy and weakness can be increased when Metocurine iodide is combined with Fluprednidene.
DB00565
The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Fluprednidene.
DB00728
The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Fluprednidene.
DB00732
The risk or severity of myopathy and weakness can be increased when Atracurium besylate is combined with Fluprednidene.
DB01135
The risk or severity of myopathy and weakness can be increased when Doxacurium is combined with Fluprednidene.
DB01226
The risk or severity of myopathy and weakness can be increased when Mivacurium is combined with Fluprednidene.
DB01336
The risk or severity of myopathy and weakness can be increased when Metocurine is combined with Fluprednidene.
DB01339
The risk or severity of myopathy and weakness can be increased when Vecuronium is combined with Fluprednidene.
DB04834
The risk or severity of myopathy and weakness can be increased when Rapacuronium is combined with Fluprednidene.
DB11156
The risk or severity of myopathy and weakness can be increased when Pyrantel is combined with Fluprednidene.
DB12989
The risk or severity of myopathy and weakness can be increased when Neosaxitoxin is combined with Fluprednidene.
DB13295
The risk or severity of myopathy and weakness can be increased when Atracurium is combined with Fluprednidene.
DB13584
The risk or severity of myopathy and weakness can be increased when Gallamine is combined with Fluprednidene.
DB13648
The risk or severity of myopathy and weakness can be increased when Alcuronium is combined with Fluprednidene.
DB03793
The therapeutic efficacy of Benzoic acid can be decreased when used in combination with Fluprednidene.
DB06819
The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Fluprednidene.
DB08909
The therapeutic efficacy of Glycerol phenylbutyrate can be decreased when used in combination with Fluprednidene.
DB09269
The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Fluprednidene.
DB01108
The risk or severity of edema formation can be increased when Trilostane is combined with Fluprednidene.
DB00624
The risk or severity of edema formation can be increased when Testosterone is combined with Fluprednidene.
DB00984
The risk or severity of edema formation can be increased when Nandrolone phenpropionate is combined with Fluprednidene.
DB01420
The risk or severity of edema formation can be increased when Testosterone propionate is combined with Fluprednidene.
DB01434
The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Fluprednidene.
DB01456
The risk or severity of edema formation can be increased when 5-androstenedione is combined with Fluprednidene.
DB01471
The risk or severity of edema formation can be increased when Bolasterone is combined with Fluprednidene.
DB01481
The risk or severity of edema formation can be increased when 1-Testosterone is combined with Fluprednidene.
DB01485
The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Fluprednidene.
DB01521
The risk or severity of edema formation can be increased when Clostebol is combined with Fluprednidene.
DB01524
The risk or severity of edema formation can be increased when Androstenediol is combined with Fluprednidene.
DB01536
The risk or severity of edema formation can be increased when Androstenedione is combined with Fluprednidene.
DB01541
The risk or severity of edema formation can be increased when Boldenone is combined with Fluprednidene.
DB01554
The risk or severity of edema formation can be increased when Bolandiol is combined with Fluprednidene.
DB01564
The risk or severity of edema formation can be increased when Calusterone is combined with Fluprednidene.
DB05107
The risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Fluprednidene.
DB05804
The risk or severity of edema formation can be increased when Prasterone sulfate is combined with Fluprednidene.
DB05830
The risk or severity of edema formation can be increased when Trestolone is combined with Fluprednidene.
DB06250
The risk or severity of edema formation can be increased when Fluasterone is combined with Fluprednidene.
DB06710
The risk or severity of edema formation can be increased when Methyltestosterone is combined with Fluprednidene.
DB07768
The risk or severity of edema formation can be increased when Epitestosterone is combined with Fluprednidene.
DB08619
The risk or severity of edema formation can be increased when Testosterone succinate is combined with Fluprednidene.
DB08804
The risk or severity of edema formation can be increased when Nandrolone decanoate is combined with Fluprednidene.
DB08905
The risk or severity of edema formation can be increased when Formestane is combined with Fluprednidene.
DB09123
The risk or severity of edema formation can be increased when Dienogest is combined with Fluprednidene.
DB11429
The risk or severity of edema formation can be increased when Mibolerone is combined with Fluprednidene.
DB12194
The risk or severity of edema formation can be increased when Atamestane is combined with Fluprednidene.
DB13169
The risk or severity of edema formation can be increased when Nandrolone is combined with Fluprednidene.
DB13587
The risk or severity of edema formation can be increased when Mesterolone is combined with Fluprednidene.
DB13710
The risk or severity of edema formation can be increased when Metenolone is combined with Fluprednidene.
DB13943
The risk or severity of edema formation can be increased when Testosterone cypionate is combined with Fluprednidene.
DB13944
The risk or severity of edema formation can be increased when Testosterone enanthate is combined with Fluprednidene.
DB13946
The risk or severity of edema formation can be increased when Testosterone undecanoate is combined with Fluprednidene.
DB13947
The risk or severity of edema formation can be increased when Testosterone enantate benzilic acid hydrazone is combined with Fluprednidene.
DB13958
The risk or severity of edema formation can be increased when Trestolone acetate is combined with Fluprednidene.
DB11988
Ocrelizumab may increase the immunosuppressive activities of Fluprednidene.
DB11642
The serum concentration of Fluprednidene can be decreased when it is combined with Pitolisant.
DB09046
The metabolism of Fluprednidene can be increased when combined with Metreleptin.
DB00186
The metabolism of Lorazepam can be increased when combined with Fluprednidene.
DB00191
The metabolism of Phentermine can be increased when combined with Fluprednidene.
DB00207
The metabolism of Azithromycin can be increased when combined with Fluprednidene.
DB00208
The metabolism of Ticlopidine can be increased when combined with Fluprednidene.
DB00246
The metabolism of Ziprasidone can be increased when combined with Fluprednidene.
DB00264
The metabolism of Metoprolol can be increased when combined with Fluprednidene.
DB00426
The metabolism of Famciclovir can be increased when combined with Fluprednidene.
DB00433
The metabolism of Prochlorperazine can be increased when combined with Fluprednidene.
DB00476
The metabolism of Duloxetine can be increased when combined with Fluprednidene.
DB00518
The metabolism of Albendazole can be increased when combined with Fluprednidene.
DB00567
The metabolism of Cephalexin can be increased when combined with Fluprednidene.
DB00590
The metabolism of Doxazosin can be increased when combined with Fluprednidene.
DB01039
The metabolism of Fenofibrate can be increased when combined with Fluprednidene.
DB01411
The metabolism of Pranlukast can be increased when combined with Fluprednidene.
DB01431
The metabolism of Allylestrenol can be increased when combined with Fluprednidene.
DB01624
The metabolism of Zuclopenthixol can be increased when combined with Fluprednidene.
DB06201
The metabolism of Rufinamide can be increased when combined with Fluprednidene.
DB06218
The metabolism of Lacosamide can be increased when combined with Fluprednidene.
DB06480
The metabolism of Prucalopride can be increased when combined with Fluprednidene.
DB09030
The metabolism of Vorapaxar can be increased when combined with Fluprednidene.
DB09034
The metabolism of Suvorexant can be increased when combined with Fluprednidene.
DB09048
The metabolism of Netupitant can be increased when combined with Fluprednidene.
DB09071
The metabolism of Tasimelteon can be increased when combined with Fluprednidene.
DB09079
The metabolism of Nintedanib can be increased when combined with Fluprednidene.
DB09299
The metabolism of Tenofovir alafenamide can be increased when combined with Fluprednidene.
DB11273
The metabolism of Dihydroergocornine can be increased when combined with Fluprednidene.
DB11952
The metabolism of Duvelisib can be increased when combined with Fluprednidene.
DB12141
The metabolism of Gilteritinib can be increased when combined with Fluprednidene.
DB12515
The metabolism of 9-aminocamptothecin can be increased when combined with Fluprednidene.
DB12952
The metabolism of Methylprednisone can be increased when combined with Fluprednidene.
DB13345
The metabolism of Dihydroergocristine can be increased when combined with Fluprednidene.
DB13385
The metabolism of Dihydroergocryptine can be increased when combined with Fluprednidene.
DB14009
The metabolism of Medical Cannabis can be increased when combined with Fluprednidene.
DB14126
The metabolism of Tenofovir can be increased when combined with Fluprednidene.
DB00549
The metabolism of Fluprednidene can be increased when combined with Zafirlukast.
DB01098
The metabolism of Rosuvastatin can be increased when combined with Fluprednidene.
DB01072
The metabolism of Atazanavir can be increased when combined with Fluprednidene.
DB01323
The metabolism of St. John's Wort can be increased when combined with Fluprednidene.
DB11730
The metabolism of Ribociclib can be increased when combined with Fluprednidene.
DB15444
The metabolism of Elexacaftor can be increased when combined with Fluprednidene.
DB12887
The metabolism of Tazemetostat can be increased when combined with Fluprednidene.
DB06717
The metabolism of Fosaprepitant can be increased when combined with Fluprednidene.
DB12825
The metabolism of Lefamulin can be increased when combined with Fluprednidene.
DB00247
The metabolism of Methysergide can be increased when combined with Fluprednidene.
DB00454
The metabolism of Meperidine can be increased when combined with Fluprednidene.
DB11742
The metabolism of Ebastine can be increased when combined with Fluprednidene.
DB00342
The metabolism of Terfenadine can be increased when combined with Fluprednidene.
DB00604
The metabolism of Cisapride can be increased when combined with Fluprednidene.
DB11633
The metabolism of Isavuconazole can be increased when combined with Fluprednidene.
DB00188
The metabolism of Fluprednidene can be increased when combined with Bortezomib.
DB00309
The metabolism of Fluprednidene can be increased when combined with Vindesine.
DB00361
The metabolism of Fluprednidene can be increased when combined with Vinorelbine.
DB00398
The metabolism of Fluprednidene can be increased when combined with Sorafenib.
DB00444
The metabolism of Fluprednidene can be increased when combined with Teniposide.
DB00531
The metabolism of Fluprednidene can be increased when combined with Cyclophosphamide.
DB00541
The metabolism of Fluprednidene can be increased when combined with Vincristine.
DB00570
The metabolism of Fluprednidene can be increased when combined with Vinblastine.
DB00762
The metabolism of Fluprednidene can be increased when combined with Irinotecan.
DB00773
The metabolism of Fluprednidene can be increased when combined with Etoposide.
DB00997
The metabolism of Fluprednidene can be increased when combined with Doxorubicin.
DB01248
The metabolism of Fluprednidene can be increased when combined with Docetaxel.
DB04845
The metabolism of Fluprednidene can be increased when combined with Ixabepilone.
DB04868
The metabolism of Fluprednidene can be increased when combined with Nilotinib.
DB05109
The metabolism of Fluprednidene can be increased when combined with Trabectedin.
DB05773
The metabolism of Fluprednidene can be increased when combined with Trastuzumab emtansine.
DB06589
The metabolism of Fluprednidene can be increased when combined with Pazopanib.
DB06603
The metabolism of Fluprednidene can be increased when combined with Panobinostat.
DB06616
The metabolism of Fluprednidene can be increased when combined with Bosutinib.
DB06772
The metabolism of Fluprednidene can be increased when combined with Cabazitaxel.
DB08870
The metabolism of Fluprednidene can be increased when combined with Brentuximab vedotin.
DB08877
The metabolism of Fluprednidene can be increased when combined with Ruxolitinib.
DB08901
The metabolism of Fluprednidene can be increased when combined with Ponatinib.
DB08910
The metabolism of Fluprednidene can be increased when combined with Pomalidomide.
DB09054
The metabolism of Idelalisib can be increased when combined with Fluprednidene.
DB09073
The metabolism of Palbociclib can be increased when combined with Fluprednidene.
DB09074
The metabolism of Olaparib can be increased when combined with Fluprednidene.
DB11817
The metabolism of Baricitinib can be increased when combined with Fluprednidene.
DB01181
The metabolism of Fluprednidene can be increased when combined with Ifosfamide.
DB05239
The metabolism of Cobimetinib can be increased when combined with Fluprednidene.
DB09330
The metabolism of Osimertinib can be increased when combined with Fluprednidene.
DB11963
The metabolism of Dacomitinib can be increased when combined with Fluprednidene.
DB12015
The metabolism of Alpelisib can be increased when combined with Fluprednidene.
DB01100
The metabolism of Pimozide can be increased when combined with Fluprednidene.
DB01118
The metabolism of Amiodarone can be increased when combined with Fluprednidene.
DB00530
The metabolism of Erlotinib can be increased when combined with Fluprednidene.
DB00564
The metabolism of Carbamazepine can be increased when combined with Fluprednidene.
DB00675
The metabolism of Tamoxifen can be increased when combined with Fluprednidene.
DB00877
The metabolism of Sirolimus can be increased when combined with Fluprednidene.
DB01229
The metabolism of Paclitaxel can be increased when combined with Fluprednidene.
DB01254
The metabolism of Dasatinib can be increased when combined with Fluprednidene.
DB04855
The metabolism of Dronedarone can be increased when combined with Fluprednidene.
DB06176
The metabolism of Romidepsin can be increased when combined with Fluprednidene.
DB06287
The metabolism of Temsirolimus can be increased when combined with Fluprednidene.
DB06626
The metabolism of Axitinib can be increased when combined with Fluprednidene.
DB08865
The metabolism of Crizotinib can be increased when combined with Fluprednidene.
DB12483
The metabolism of Copanlisib can be increased when combined with Fluprednidene.
DB00204
The metabolism of Dofetilide can be increased when combined with Fluprednidene.
DB00277
The metabolism of Theophylline can be increased when combined with Fluprednidene.
DB00908
The metabolism of Quinidine can be increased when combined with Fluprednidene.
DB01008
The metabolism of Busulfan can be increased when combined with Fluprednidene.
DB01223
The metabolism of Aminophylline can be increased when combined with Fluprednidene.
DB01590
The metabolism of Everolimus can be increased when combined with Fluprednidene.
DB09289
The metabolism of Tianeptine can be increased when combined with Fluprednidene.
DB00563
The metabolism of Fluprednidene can be increased when combined with Methotrexate.
DB00575
The metabolism of Clonidine can be increased when combined with Fluprednidene.
DB00637
The metabolism of Astemizole can be increased when combined with Fluprednidene.
DB12371
The metabolism of Siponimod can be increased when combined with Fluprednidene.
DB08827
The metabolism of Lomitapide can be increased when combined with Fluprednidene.
DB05294
The metabolism of Vandetanib can be increased when combined with Fluprednidene.
DB08881
The metabolism of Vemurafenib can be increased when combined with Fluprednidene.
DB11363
The metabolism of Alectinib can be increased when combined with Fluprednidene.
DB11581
The metabolism of Venetoclax can be increased when combined with Fluprednidene.
DB11641
The metabolism of Vinflunine can be increased when combined with Fluprednidene.
DB11703
The metabolism of Acalabrutinib can be increased when combined with Fluprednidene.
DB13874
The metabolism of Enasidenib can be increased when combined with Fluprednidene.
DB15035
The metabolism of Zanubrutinib can be increased when combined with Fluprednidene.
DB00248
The metabolism of Cabergoline can be increased when combined with Fluprednidene.
DB06595
The metabolism of Midostaurin can be increased when combined with Fluprednidene.
DB08912
The metabolism of Dabrafenib can be increased when combined with Fluprednidene.
DB09143
The metabolism of Sonidegib can be increased when combined with Fluprednidene.
DB09570
The metabolism of Ixazomib can be increased when combined with Fluprednidene.
DB11828
The metabolism of Neratinib can be increased when combined with Fluprednidene.
DB12147
The metabolism of Erdafitinib can be increased when combined with Fluprednidene.
DB12267
The metabolism of Brigatinib can be increased when combined with Fluprednidene.
DB12978
The metabolism of Pexidartinib can be increased when combined with Fluprednidene.
DB14568
The metabolism of Ivosidenib can be increased when combined with Fluprednidene.
DB06212
The metabolism of Tolvaptan can be increased when combined with Fluprednidene.
DB08896
The metabolism of Regorafenib can be increased when combined with Fluprednidene.
DB12001
The metabolism of Abemaciclib can be increased when combined with Fluprednidene.
DB00320
The metabolism of Dihydroergotamine can be increased when combined with Fluprednidene.
DB00696
The metabolism of Ergotamine can be increased when combined with Fluprednidene.
DB00872
The metabolism of Conivaptan can be increased when combined with Fluprednidene.
DB01128
The metabolism of Bicalutamide can be increased when combined with Fluprednidene.
DB01242
The metabolism of Clomipramine can be increased when combined with Fluprednidene.
DB00540
The metabolism of Nortriptyline can be increased when combined with Fluprednidene.
DB01227
The metabolism of Levacetylmethadol can be increased when combined with Fluprednidene.
DB12130
The metabolism of Lorlatinib can be increased when combined with Fluprednidene.
DB01224
The metabolism of Quetiapine can be increased when combined with Fluprednidene.
DB01126
The metabolism of Dutasteride can be increased when combined with Fluprednidene.
DB11757
The metabolism of Istradefylline can be increased when combined with Fluprednidene.
DB04856
The metabolism of Dexloxiglumide can be increased when combined with Fluprednidene.
DB04957
The metabolism of Azimilide can be increased when combined with Fluprednidene.
DB00199
The metabolism of Erythromycin can be increased when combined with Fluprednidene.
DB00238
The metabolism of Nevirapine can be increased when combined with Fluprednidene.
DB00250
The metabolism of Dapsone can be increased when combined with Fluprednidene.
DB00281
The metabolism of Lidocaine can be increased when combined with Fluprednidene.
DB00317
The metabolism of Gefitinib can be increased when combined with Fluprednidene.
DB00333
The metabolism of Methadone can be increased when combined with Fluprednidene.
DB00343
The metabolism of Diltiazem can be increased when combined with Fluprednidene.
DB00439
The metabolism of Cerivastatin can be increased when combined with Fluprednidene.
DB00497
The metabolism of Oxycodone can be increased when combined with Fluprednidene.
DB00499
The metabolism of Flutamide can be increased when combined with Fluprednidene.
DB00514
The metabolism of Dextromethorphan can be increased when combined with Fluprednidene.
DB00528
The metabolism of Lercanidipine can be increased when combined with Fluprednidene.
DB00571
The metabolism of Propranolol can be increased when combined with Fluprednidene.
DB00608
The metabolism of Chloroquine can be increased when combined with Fluprednidene.
DB00656
The metabolism of Trazodone can be increased when combined with Fluprednidene.
DB00661
The metabolism of Verapamil can be increased when combined with Fluprednidene.
DB00701
The metabolism of Amprenavir can be increased when combined with Fluprednidene.
DB00734
The metabolism of Risperidone can be increased when combined with Fluprednidene.
DB00758
The metabolism of Clopidogrel can be increased when combined with Fluprednidene.
DB00822
The metabolism of Disulfiram can be increased when combined with Fluprednidene.
DB00829
The metabolism of Diazepam can be increased when combined with Fluprednidene.
DB00904
The metabolism of Ondansetron can be increased when combined with Fluprednidene.
DB00909
The metabolism of Zonisamide can be increased when combined with Fluprednidene.
DB00916
The metabolism of Metronidazole can be increased when combined with Fluprednidene.
DB00921
The metabolism of Buprenorphine can be increased when combined with Fluprednidene.
DB00962
The metabolism of Zaleplon can be increased when combined with Fluprednidene.
DB00972
The metabolism of Azelastine can be increased when combined with Fluprednidene.
DB00976
The metabolism of Telithromycin can be increased when combined with Fluprednidene.
DB01054
The metabolism of Nitrendipine can be increased when combined with Fluprednidene.
DB01058
The metabolism of Praziquantel can be increased when combined with Fluprednidene.
DB01062
The metabolism of Oxybutynin can be increased when combined with Fluprednidene.
DB01076
The metabolism of Atorvastatin can be increased when combined with Fluprednidene.
DB01095
The metabolism of Fluvastatin can be increased when combined with Fluprednidene.
DB01103
The metabolism of Quinacrine can be increased when combined with Fluprednidene.
DB01114
The metabolism of Chlorpheniramine can be increased when combined with Fluprednidene.
DB01166
The metabolism of Cilostazol can be increased when combined with Fluprednidene.
DB01184
The metabolism of Domperidone can be increased when combined with Fluprednidene.
DB01211
The metabolism of Clarithromycin can be increased when combined with Fluprednidene.
DB01216
The metabolism of Finasteride can be increased when combined with Fluprednidene.
DB01218
The metabolism of Halofantrine can be increased when combined with Fluprednidene.
DB01238
The metabolism of Aripiprazole can be increased when combined with Fluprednidene.
DB01259
The metabolism of Lapatinib can be increased when combined with Fluprednidene.
DB01267
The metabolism of Paliperidone can be increased when combined with Fluprednidene.
DB04946
The metabolism of Iloperidone can be increased when combined with Fluprednidene.
DB05521
The metabolism of Telaprevir can be increased when combined with Fluprednidene.
DB06267
The metabolism of Udenafil can be increased when combined with Fluprednidene.
DB06403
The metabolism of Ambrisentan can be increased when combined with Fluprednidene.
DB06419
The metabolism of Cethromycin can be increased when combined with Fluprednidene.
DB06605
The metabolism of Apixaban can be increased when combined with Fluprednidene.
DB06652
The metabolism of Vicriviroc can be increased when combined with Fluprednidene.
DB06697
The metabolism of Artemether can be increased when combined with Fluprednidene.
DB08820
The metabolism of Ivacaftor can be increased when combined with Fluprednidene.
DB08873
The metabolism of Boceprevir can be increased when combined with Fluprednidene.
DB08883
The metabolism of Perampanel can be increased when combined with Fluprednidene.
DB08899
The metabolism of Enzalutamide can be increased when combined with Fluprednidene.
DB09061
The metabolism of Cannabidiol can be increased when combined with Fluprednidene.
DB09065
The metabolism of Cobicistat can be increased when combined with Fluprednidene.
DB09068
The metabolism of Vortioxetine can be increased when combined with Fluprednidene.
DB09102
The metabolism of Daclatasvir can be increased when combined with Fluprednidene.
DB09231
The metabolism of Benidipine can be increased when combined with Fluprednidene.
DB09297
The metabolism of Paritaprevir can be increased when combined with Fluprednidene.
DB11574
The metabolism of Elbasvir can be increased when combined with Fluprednidene.
DB11586
The metabolism of Asunaprevir can be increased when combined with Fluprednidene.
DB11712
The metabolism of Tezacaftor can be increased when combined with Fluprednidene.
DB11737
The metabolism of Icotinib can be increased when combined with Fluprednidene.
DB11915
The metabolism of Valbenazine can be increased when combined with Fluprednidene.
DB12161
The metabolism of Deutetrabenazine can be increased when combined with Fluprednidene.
DB12301
The metabolism of Doravirine can be increased when combined with Fluprednidene.
DB13952
The metabolism of Estradiol acetate can be increased when combined with Fluprednidene.
DB13955
The metabolism of Estradiol dienanthate can be increased when combined with Fluprednidene.
DB14011
The metabolism of Nabiximols can be increased when combined with Fluprednidene.
DB14185
The metabolism of Aripiprazole lauroxil can be increased when combined with Fluprednidene.
DB09237
The metabolism of Levamlodipine can be increased when combined with Fluprednidene.
DB11951
The metabolism of Lemborexant can be increased when combined with Fluprednidene.
DB00557
The metabolism of Hydroxyzine can be increased when combined with Fluprednidene.
DB01115
The metabolism of Nifedipine can be increased when combined with Fluprednidene.
DB00203
The metabolism of Sildenafil can be increased when combined with Fluprednidene.
DB00227
The metabolism of Lovastatin can be increased when combined with Fluprednidene.
DB00490
The metabolism of Buspirone can be increased when combined with Fluprednidene.
DB00641
The metabolism of Simvastatin can be increased when combined with Fluprednidene.
DB00673
The metabolism of Aprepitant can be increased when combined with Fluprednidene.
DB00820
The metabolism of Tadalafil can be increased when combined with Fluprednidene.
DB00862
The metabolism of Vardenafil can be increased when combined with Fluprednidene.
DB01190
The metabolism of Clindamycin can be increased when combined with Fluprednidene.
DB00321
The metabolism of Amitriptyline can be increased when combined with Fluprednidene.
DB00224
The metabolism of Indinavir can be increased when combined with Fluprednidene.
DB00401
The metabolism of Nisoldipine can be increased when combined with Fluprednidene.
DB00404
The metabolism of Alprazolam can be increased when combined with Fluprednidene.
DB00683
The metabolism of Midazolam can be increased when combined with Fluprednidene.
DB00700
The metabolism of Eplerenone can be increased when combined with Fluprednidene.
DB00802
The metabolism of Alfentanil can be increased when combined with Fluprednidene.
DB00813
The metabolism of Fentanyl can be increased when combined with Fluprednidene.
DB00897
The metabolism of Triazolam can be increased when combined with Fluprednidene.
DB01023
The metabolism of Felodipine can be increased when combined with Fluprednidene.
DB01232
The metabolism of Saquinavir can be increased when combined with Fluprednidene.
DB06228
The metabolism of Rivaroxaban can be increased when combined with Fluprednidene.
DB11689
The metabolism of Selumetinib can be increased when combined with Fluprednidene.
DB00714
The metabolism of Apomorphine can be increased when combined with Fluprednidene.
DB00741
The metabolism of Hydrocortisone can be increased when combined with Fluprednidene.
DB14541
The metabolism of Hydrocortisone cypionate can be increased when combined with Fluprednidene.
DB00655
The metabolism of Estrone can be increased when combined with Fluprednidene.
DB06448
The metabolism of Lonafarnib can be increased when combined with Fluprednidene.
DB14542
The metabolism of Hydrocortisone phosphate can be increased when combined with Fluprednidene.
DB09256
The metabolism of Tegafur can be increased when combined with Fluprednidene.
DB00091
Fluprednidene may increase the immunosuppressive activities of Cyclosporine.
DB13074
The therapeutic efficacy of Macimorelin can be decreased when used in combination with Fluprednidene.
DB00381
The metabolism of Amlodipine can be increased when combined with Fluprednidene.
DB00024
The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Fluprednidene.
DB00279
The therapeutic efficacy of Liothyronine can be decreased when used in combination with Fluprednidene.
DB01583
The therapeutic efficacy of Liotrix can be decreased when used in combination with Fluprednidene.
DB03604
The therapeutic efficacy of Tiratricol can be decreased when used in combination with Fluprednidene.
DB09100
The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Fluprednidene.
DB00451
The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Fluprednidene.
DB00425
The metabolism of Zolpidem can be increased when combined with Fluprednidene.
DB00331
The therapeutic efficacy of Metformin can be decreased when used in combination with Fluprednidene.
DB00945
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Acetylsalicylic acid.
DB11986
The metabolism of Entrectinib can be increased when combined with Fluprednidene.
DB01432
Cholestyramine may increase the excretion rate of Fluprednidene which could result in a lower serum level and potentially a reduction in efficacy.
DB00388
The risk or severity of hypertension can be increased when Fluprednidene is combined with Phenylephrine.
DB00357
The therapeutic efficacy of Fluprednidene can be decreased when used in combination with Aminoglutethimide.
DB01268
The risk or severity of hyperglycemia can be increased when Sunitinib is combined with Fluprednidene.
DB00030
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Insulin human.
DB00046
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Insulin lispro.
DB00047
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Insulin glargine.
DB00071
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Insulin pork.
DB00197
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Troglitazone.
DB00222
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Glimepiride.
DB00263
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Sulfisoxazole.
DB00280
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Disopyramide.
DB00284
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Acarbose.
DB00359
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Sulfadiazine.
DB00412
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Rosiglitazone.
DB00414
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Acetohexamide.
DB00468
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Quinine.
DB00491
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Miglitol.
DB00672
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Chlorpropamide.
DB00731
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Nateglinide.
DB00738
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Pentamidine.
DB00839
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Tolazamide.
DB00912
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Repaglinide.
DB00914
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Phenformin.
DB01016
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Glyburide.
DB01067
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Glipizide.
DB01120
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Gliclazide.
DB01124
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Tolbutamide.
DB01132
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Pioglitazone.
DB01251
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Gliquidone.
DB01252
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Mitiglinide.
DB01261
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Sitagliptin.
DB01276
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Exenatide.
DB01277
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Mecasermin.
DB01278
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Pramlintide.
DB01289
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Glisoxepide.
DB01306
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Insulin aspart.
DB01307
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Insulin detemir.
DB01309
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Insulin glulisine.
DB01382
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Glymidine.
DB01700
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with AICA ribonucleotide.
DB04830
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Buformin.
DB04876
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Vildagliptin.
DB04878
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Voglibose.
DB05115
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with NN344.
DB05819
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with NBI-6024.
DB06011
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with AMG-222.
DB06127
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Bisegliptin.
DB06203
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Alogliptin.
DB06292
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Dapagliflozin.
DB06335
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Saxagliptin.
DB06655
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Liraglutide.
DB08382
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Gosogliptin.
DB08882
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Linagliptin.
DB08907
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Canagliflozin.
DB08962
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Glibornuride.
DB09022
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Benfluorex.
DB09038
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Empagliflozin.
DB09043
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Albiglutide.
DB09045
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Dulaglutide.
DB09198
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Lobeglitazone.
DB09199
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Netoglitazone.
DB09200
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Rivoglitazone.
DB09201
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Ciglitazone.
DB09265
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Lixisenatide.
DB09456
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Insulin beef.
DB09564
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Insulin degludec.
DB11567
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Insulin peglispro.
DB11568
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Insulin tregopil.
DB11698
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Ipragliflozin.
DB11723
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Dutogliptin.
DB11780
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Allicin.
DB11824
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Tofogliflozin.
DB11827
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Ertugliflozin.
DB11898
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with 2,4-thiazolidinedione.
DB11950
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Teneligliptin.
DB11992
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Omarigliptin.
DB12268
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Carmegliptin.
DB12412
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Gemigliptin.
DB12417
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Anagliptin.
DB12625
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Evogliptin.
DB12713
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Sotagliflozin.
DB12781
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Balaglitazone.
DB12935
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Remogliflozin etabonate.
DB13406
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Carbutamide.
DB13446
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Guar gum.
DB13675
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Metahexamide.
DB13928
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Semaglutide.
DB14027
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Taspoglutide.
DB14035
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Englitazone.
DB15171
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Tirzepatide.
DB15217
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Gastric inhibitory polypeptide.
DB01200
The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Bromocriptine.
DB00951
The serum concentration of Isoniazid can be decreased when it is combined with Fluprednidene.
DB01396
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Digitoxin.
DB00390
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Digoxin.
DB00511
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Acetyldigitoxin.
DB01078
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Deslanoside.
DB13401
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Metildigoxin.
DB13467
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Lanatoside C.
DB13537
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Gitoformate.
DB13691
The risk or severity of adverse effects can be increased when Fluprednidene is combined with Acetyldigoxin.
DB04914
The therapeutic efficacy of G17DT can be decreased when used in combination with Fluprednidene.
DB05144
The therapeutic efficacy of PEV3A can be decreased when used in combination with Fluprednidene.
DB05325
The therapeutic efficacy of INGN 225 can be decreased when used in combination with Fluprednidene.
DB05374
The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Fluprednidene.
DB05440
The therapeutic efficacy of SRP 299 can be decreased when used in combination with Fluprednidene.
DB05942
The therapeutic efficacy of GI-5005 can be decreased when used in combination with Fluprednidene.
DB06400
The therapeutic efficacy of Vitespen can be decreased when used in combination with Fluprednidene.
DB06584
The therapeutic efficacy of TG4010 can be decreased when used in combination with Fluprednidene.
DB09057
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Fluprednidene.
DB10062
The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Fluprednidene.
DB10076
The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Fluprednidene.
DB10276
The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Fluprednidene.
DB10283
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Fluprednidene.
DB10342
The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Fluprednidene.
DB10583
The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fluprednidene.
DB10584
The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Fluprednidene.
DB10600
The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Fluprednidene.
DB10769
The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Fluprednidene.
DB10794
The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) can be decreased when used in combination with Fluprednidene.
DB10803
The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Fluprednidene.
DB10989
The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Fluprednidene.
DB10990
The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Fluprednidene.
DB11038
The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Fluprednidene.
DB11040
The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Fluprednidene.
DB11041
The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Fluprednidene.
DB11044
The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Fluprednidene.
DB11603
The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Fluprednidene.
DB11627
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Fluprednidene.
DB12568
The therapeutic efficacy of Tecemotide can be decreased when used in combination with Fluprednidene.
DB14022
The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Fluprednidene.
DB14384
The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Fluprednidene.
DB14385
The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Fluprednidene.
DB14394
The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Fluprednidene.
DB14445
The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Fluprednidene.
DB14449
The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Fluprednidene.
DB14619
The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Fluprednidene.
DB14620
The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Fluprednidene.
DB14711
The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Fluprednidene.
DB15274
The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Fluprednidene.
DB15461
The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Fluprednidene.
DB10317
The therapeutic efficacy of Fluprednidene can be decreased when used in combination with Rubella virus vaccine.
DB10318
The therapeutic efficacy of Fluprednidene can be decreased when used in combination with Varicella Zoster Vaccine (Live/attenuated).
DB10343
The therapeutic efficacy of Fluprednidene can be decreased when used in combination with Bacillus calmette-guerin substrain tice live antigen.
DB10804
The therapeutic efficacy of Fluprednidene can be decreased when used in combination with Bacillus calmette-guerin substrain connaught live antigen.
DB10805
The therapeutic efficacy of Fluprednidene can be decreased when used in combination with Yellow Fever Vaccine.
DB11003
The therapeutic efficacy of Fluprednidene can be decreased when used in combination with Anthrax vaccine.
DB11050
The therapeutic efficacy of Fluprednidene can be decreased when used in combination with Typhoid Vaccine Live.
DB12386
The therapeutic efficacy of Fluprednidene can be decreased when used in combination with Bacillus calmette-guerin substrain danish 1331 live antigen.
DB12768
The therapeutic efficacy of Fluprednidene can be decreased when used in combination with BCG vaccine.
DB14409
The therapeutic efficacy of Fluprednidene can be decreased when used in combination with Human adenovirus e serotype 4 strain cl-68578 antigen.
DB14443
The therapeutic efficacy of Fluprednidene can be decreased when used in combination with Vibrio cholerae CVD 103-HgR strain live antigen.
DB14685
The therapeutic efficacy of Fluprednidene can be decreased when used in combination with Adenovirus type 7 vaccine live.
DB13924
The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Fluprednidene.
DB15483
The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Fluprednidene.
DB15595
The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Fluprednidene.
DB15654
The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Fluprednidene.
DB06119
The serum concentration of Cenobamate can be decreased when it is combined with Fluprednidene.
DB01364
Ephedrine may increase the excretion rate of Fluprednidene which could result in a lower serum level and potentially a reduction in efficacy.
DB00052
The therapeutic efficacy of Somatotropin can be decreased when used in combination with Fluprednidene.
DB01320
The serum concentration of Fosphenytoin can be decreased when it is combined with Fluprednidene.
DB00252
The serum concentration of Fluprednidene can be decreased when it is combined with Phenytoin.
DB14513
The serum concentration of Magnesium can be decreased when it is combined with Fluprednidene.
DB01601
The serum concentration of Fluprednidene can be increased when it is combined with Lopinavir.
DB00503
The serum concentration of Ritonavir can be increased when it is combined with Fluprednidene.
DB00232
The risk or severity of electrolyte imbalance can be increased when Fluprednidene is combined with Methyclothiazide.
DB00436
The risk or severity of electrolyte imbalance can be increased when Fluprednidene is combined with Bendroflumethiazide.
DB00562
The risk or severity of electrolyte imbalance can be increased when Fluprednidene is combined with Benzthiazide.
DB00774
The risk or severity of electrolyte imbalance can be increased when Fluprednidene is combined with Hydroflumethiazide.
DB00880
The risk or severity of electrolyte imbalance can be increased when Fluprednidene is combined with Chlorothiazide.
DB00999
The risk or severity of electrolyte imbalance can be increased when Fluprednidene is combined with Hydrochlorothiazide.
DB01021
The risk or severity of electrolyte imbalance can be increased when Fluprednidene is combined with Trichlormethiazide.
DB01324
The risk or severity of electrolyte imbalance can be increased when Fluprednidene is combined with Polythiazide.
DB13532
The risk or severity of electrolyte imbalance can be increased when Fluprednidene is combined with Cyclopenthiazide.
DB00606
The risk or severity of electrolyte imbalance can be increased when Fluprednidene is combined with Cyclothiazide.
DB13430
The risk or severity of electrolyte imbalance can be increased when Fluprednidene is combined with Mebutizide.
DB00502
The serum concentration of Haloperidol can be increased when it is combined with Fluprednidene.
DB11652
The metabolism of Tucatinib can be decreased when combined with Fluprednidene.
DB12530
The risk or severity of infection can be increased when Fluprednidene is combined with Inebilizumab.
DB11932
The serum concentration of Fluprednidene can be increased when it is combined with Abametapir.
DB15762
The serum concentration of Fluprednidene can be decreased when it is combined with Satralizumab.
DB15093
The serum concentration of the active metabolites of Fluprednidene can be decreased when Fluprednidene is used in combination with Somapacitan.
序列
实验性质
外部标识符
resource:ChEBI
identifier:135989
resource:PubChem Compound
identifier:11794741
resource:PubChem Substance
identifier:310264933
resource:ChemSpider
identifier:9969413
resource:Wikipedia
identifier:Fluprednidene
resource:ChEMBL
identifier:CHEMBL2106763
resource:ZINC
identifier:ZINC000004213363
resource:RxCUI
identifier:236650
外部链接
路径
目标
BE0002638Cytochrome P450 3A4HumanssubstrateinducerA18131620482443Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462.noCytochrome P450 3A4Vitamin d3 25-hydroxylase activityCytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide (PubMed:11159812). Catalyzes 4-beta-hydroxylation of cholesterol. May catalyze 25-hydroxylation of cholesterol in vitro (PubMed:21576599).CYP3A47q21.1Endoplasmic reticulum membrane2-228.2557342.677HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:2637GenAtlasCYP3A4GenBank Gene DatabaseM18907Guide to Pharmacology1337UniProtKBP08684UniProt AccessionCP3A4_HUMAN1,8-cineole 2-exo-monooxygenase1.14.13.-Albendazole monooxygenaseAlbendazole sulfoxidaseCholesterol 25-hydroxylaseCYP3A3CYPIIIA3CYPIIIA4Cytochrome P450 3A3Cytochrome P450 HLpCytochrome P450 NF-25Cytochrome P450-PCN1Nifedipine oxidaseQuinine 3-monooxygenaseTaurochenodeoxycholate 6-alpha-hydroxylase>lcl|BSEQ0021936|Cytochrome P450 3A4 MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG GLLQPEKPVVLKVESRDGTVSGA>lcl|BSEQ0021937|Cytochrome P450 3A4 (CYP3A4) ATGGCTCTCATCCCAGACTTGGCCATGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG CTCCTCTATCTATATGGAACCCATTCACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG CCCACACCTCTGCCTTTTTTGGGAAATATTTTGTCCTACCATAAGGGCTTTTGTATGTTT GACATGGAATGTCATAAAAAGTATGGAAAAGTGTGGGGCTTTTATGATGGTCAACAGCCT GTGCTGGCTATCACAGATCCTGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT GTCTTCACAAACCGGAGGCCTTTTGGTCCAGTGGGATTTATGAAAAGTGCCATCTCTATA GCTGAGGATGAAGAATGGAAGAGATTACGATCATTGCTGTCTCCAACCTTCACCAGTGGA AAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG AGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAAGACGTCTTTGGGGCCTACAGC ATGGATGTGATCACTAGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA GACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTGATTTTTTGGATCCATTCTTT CTCTCAATAATCTTTCCATTCCTCATCCCAATTCTTGAAGTATTAAATATCTGTGTGTTT CCAAGAGAAGTTACAAATTTTTTAAGAAAATCTGTAAAAAGGATGAAAGAAAGTCGCCTC GAAGATACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAATTCA AAAGAAACTGAGTCCCACAAAGCTCTGTCCGATCTGGAGCTCGTGGCCCAATCAATTATC TTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATGTATGAACTG GCCACTCACCCTGATGTCCAGCAGAAACTGCAGGAGGAAATTGATGCAGTTTTACCCAAT AAGGCACCACCCACCTATGATACTGTGCTACAGATGGAGTATCTTGACATGGTGGTGAAT GAAACGCTCAGATTATTCCCAATTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGATGTT GAGATCAATGGGATGTTCATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGCTCTT CACCGTGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGATTCAGCAAG AAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGAAAC TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTAAGCTTAGGAGGA CTTCTTCAACCAGAAAAACCCGTTGTTCTAAAGGTTGAGTCAAGGGATGGCACCGTAAGT GGAGCCTGAPF00067p450componentcytoplasmcomponentendoplasmic reticulum membranecomponentintegral component of membranecomponentintracellular membrane-bounded organellefunctionalbendazole monooxygenase activityfunctionaromatase activityfunctioncaffeine oxidase activityfunctionenzyme bindingfunctionheme bindingfunctioniron ion bindingfunctionmonooxygenase activityfunctionoxidoreductase activityfunctionoxygen bindingfunctionquinine 3-monooxygenase activityfunctionsteroid bindingfunctionsteroid hydroxylase activityfunctiontaurochenodeoxycholate 6alpha-hydroxylase activityfunctiontestosterone 6-beta-hydroxylase activityfunctionvitamin D 24-hydroxylase activityfunctionvitamin D3 25-hydroxylase activityprocessalkaloid catabolic processprocessandrogen metabolic processprocesscalcitriol biosynthetic process from calciolprocessdrug catabolic processprocessdrug metabolic processprocessexogenous drug catabolic processprocessheterocycle metabolic processprocesslipid metabolic processprocessmonoterpenoid metabolic processprocessoxidation-reduction processprocessoxidative demethylationprocesssmall molecule metabolic processprocesssteroid catabolic processprocesssteroid metabolic processprocessvitamin D metabolic processprocessxenobiotic metabolic processunknownBE0002362Cytochrome P450 3A5HumansinducerA18131620482443Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462.unknownCytochrome P450 3A5Oxygen bindingCytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.CYP3A57q21.1Endoplasmic reticulum membrane9.0957108.0657HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:2638GenAtlasCYP3A5GenBank Gene DatabaseJ04813GenBank Protein Database181346Guide to Pharmacology1338UniProtKBP20815UniProt AccessionCP3A5_HUMAN1.14.14.1CYPIIIA5Cytochrome P450 HLp2Cytochrome P450-PCN3>lcl|BSEQ0004639|Cytochrome P450 3A5 MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNVLSYRQGLWKF DTECYKKYGKMWGTYEGQLPVLAITDPDVIRTVLVKECYSVFTNRRSLGPVGFMKSAISL AEDEEWKRIRSLLSPTFTSGKLKEMFPIIAQYGDVLVRNLRREAEKGKPVTLKDIFGAYS MDVITGTSFGVNIDSLNNPQDPFVESTKKFLKFGFLDPLFLSIILFPFLTPVFEALNVSL FPKDTINFLSKSVNRMKKSRLNDKQKHRLDFLQLMIDSQNSKETESHKALSDLELAAQSI IFIFAGYETTSSVLSFTLYELATHPDVQQKLQKEIDAVLPNKAPPTYDAVVQMEYLDMVV NETLRLFPVAIRLERTCKKDVEINGVFIPKGSMVVIPTYALHHDPKYWTEPEEFRPERFS KKKDSIDPYIYTPFGTGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLDTQG LLQPEKPIVLKVDSRDGTLSGE>lcl|BSEQ0016766|Cytochrome P450 3A5 (CYP3A5) ATGGACCTCATCCCAAATTTGGCGGTGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG CTCCTCTATCTATATGGGACCCGTACACATGGACTTTTTAAGAGACTGGGAATTCCAGGG CCCACACCTCTGCCTTTGTTGGGAAATGTTTTGTCCTATCGTCAGGGTCTCTGGAAATTT GACACAGAGTGCTATAAAAAGTATGGAAAAATGTGGGGAACGTATGAAGGTCAACTCCCT GTGCTGGCCATCACAGATCCCGACGTGATCAGAACAGTGCTAGTGAAAGAATGTTATTCT GTCTTCACAAATCGAAGGTCTTTAGGCCCAGTGGGATTTATGAAAAGTGCCATCTCTTTA GCTGAGGATGAAGAATGGAAGAGAATACGGTCATTGCTGTCTCCAACCTTCACCAGCGGA AAACTCAAGGAGATGTTCCCCATCATTGCCCAGTATGGAGATGTATTGGTGAGAAACTTG AGGCGGGAAGCAGAGAAAGGCAAGCCTGTCACCTTGAAAGACATCTTTGGGGCCTACAGC ATGGATGTGATTACTGGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA GACCCCTTTGTGGAGAGCACTAAGAAGTTCCTAAAATTTGGTTTCTTAGATCCATTATTT CTCTCAATAATACTCTTTCCATTCCTTACCCCAGTTTTTGAAGCATTAAATGTCTCTCTG TTTCCAAAAGATACCATAAATTTTTTAAGTAAATCTGTAAACAGAATGAAGAAAAGTCGC CTCAACGACAAACAAAAGCACCGACTAGATTTCCTTCAGCTGATGATTGACTCCCAGAAT TCGAAAGAAACTGAGTCCCACAAAGCTCTGTCTGATCTGGAGCTCGCAGCCCAGTCAATA ATCTTCATTTTTGCTGGCTATGAAACCACCAGCAGTGTTCTTTCCTTCACTTTATATGAA CTGGCCACTCACCCTGATGTCCAGCAGAAACTGCAAAAGGAGATTGATGCAGTTTTGCCC AATAAGGCACCACCTACCTATGATGCCGTGGTACAGATGGAGTACCTTGACATGGTGGTG AATGAAACACTCAGATTATTCCCAGTTGCTATTAGACTTGAGAGGACTTGCAAGAAAGAT GTTGAAATCAATGGGGTATTCATTCCCAAAGGGTCAATGGTGGTGATTCCAACTTATGCT CTTCACCATGACCCAAAGTACTGGACAGAGCCTGAGGAGTTCCGCCCTGAAAGGTTCAGT AAGAAGAAGGACAGCATAGATCCTTACATATACACACCCTTTGGAACTGGACCCAGAAAC TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCTTGAAATTAGACACGCAAGGA CTTCTTCAACCAGAAAAACCCATTGTTCTAAAGGTGGATTCAAGAGATGGAACCCTAAGT GGAGAATGAPF00067p450componentendoplasmic reticulum membranecomponentintracellular membrane-bounded organellefunctionaromatase activityfunctionheme bindingfunctioniron ion bindingfunctionmonooxygenase activityfunctionoxidoreductase activityfunctionoxygen bindingprocessalkaloid catabolic processprocessdrug catabolic processprocessoxidative demethylationprocesssmall molecule metabolic processprocesssteroid metabolic processprocessxenobiotic metabolic processunknown
载体
运输工具
药物反应
效应
不良反应